Veldink J H, Kalmijn S, Van der Hout A H, Lemmink H H, Groeneveld G J, Lummen C, Scheffer H, Wokke J H J, Van den Berg L H
Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Center, Utrecht, The Netherlands.
Neurology. 2005 Sep 27;65(6):820-5. doi: 10.1212/01.wnl.0000174472.03292.dd. Epub 2005 Aug 10.
ALS is believed to be multifactorial in origin with modifying genes affecting its clinical expression. Childhood-onset spinal muscular atrophy (SMA) is an autosomal recessive disorder of motor neurons, caused by mutations of the survival motor neuron (SMN) gene. The SMN gene exists in two highly homologous variants: SMN1, the causative gene responsible for the production of the majority of functional SMN protein, and SMN2, responsible for the production of less protein but sufficient for modifying the SMA phenotype.
To test whether SMN genotypes are associated with susceptibility to and severity of sporadic ALS.
We performed competitive quantitative PCR analysis for both SMN1 and SMN2 genes in 242 clinically well-defined ALS patients and 175 controls. The combined determination of SMN1 and SMN2 copies also allowed for an estimation of the level of SMN for each patient (estimated SMN protein level = SMN1 copy number + 0.20 x SMN2 copy number).
One copy of SMN1 was associated with an increased risk of developing ALS (odds ratio = 4.1, 95% CI = 1.2 to 14.2, p = 0.02) and ALS patients carried fewer SMN2 copy numbers (p < 0.001). Sixty-one percent of patients had an estimated protein SMN level < or = 2.2 vs only 36% of controls (p = 0.0000004). Multivariate Cox regression analyses showed that lower SMN2 copy numbers and lower levels of estimated SMN protein (hazard ratio = 1.3, 95% CI = 1.1 to 1.6, p = 0.03) were associated with an increased mortality rate.
SMN genotypes producing less SMN protein increase susceptibility to and severity of ALS.
肌萎缩侧索硬化症(ALS)被认为起源于多因素,修饰基因影响其临床表型。儿童期发病的脊髓性肌萎缩症(SMA)是一种常染色体隐性运动神经元疾病,由存活运动神经元(SMN)基因突变引起。SMN基因存在两种高度同源的变体:SMN1,是负责产生大部分功能性SMN蛋白的致病基因;以及SMN2,负责产生较少的蛋白,但足以修饰SMA表型。
测试SMN基因型是否与散发性ALS的易感性和严重程度相关。
我们对242例临床明确诊断的ALS患者和175例对照进行了SMN1和SMN2基因的竞争性定量PCR分析。对SMN1和SMN2拷贝数的联合测定还可以估计每位患者的SMN水平(估计的SMN蛋白水平=SMN1拷贝数+0.20×SMN2拷贝数)。
一份拷贝的SMN1与发生ALS的风险增加相关(优势比=4.1,95%可信区间=1.2至14.2,p=0.02),且ALS患者携带的SMN2拷贝数较少(p<0.001)。61%的患者估计的SMN蛋白水平≤2.2,而对照组仅为36%(p=0.0000004)。多变量Cox回归分析显示,较低的SMN2拷贝数和较低的估计SMN蛋白水平(风险比=1.3,95%可信区间=1.1至1.6,p=0.03)与死亡率增加相关。
产生较少SMN蛋白的SMN基因型会增加ALS的易感性和严重程度。